TLX
Trans-Lux Corp.
NASDAQ · Healthcare · Biotechnology · AU
$10.74
+0.47%Year over year
Reported trailing growth
- Revenue
- +10.5%
- EBITDA
- -52.4%
- EBIT
- —
- EPS
- +26.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -88.2%
- EBITDA
- -63.7%
- EPS
- —
Three-year CAGR
- Revenue
- +96.0%
- EBITDA
- +86.4%
- EBIT
- +29.7%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026